Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections

October 22, 2020 11:00 AM Eastern Daylight Time GAITHERSBURG, MD–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of multi-drug resistant infectious diseases, today announced the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for the treatment of prosthetic joint infections […]

APT named 2020 Emerging Life Science Company of the Year

October 16, 2020

News

Comments Off on APT named 2020 Emerging Life Science Company of the Year

The Maryland Tech Council (MTC), Maryland’s largest technology and life sciences trade association, announced the winners of its 32nd Annual Industry Awards. Due to COVID-19, the association pivoted to a virtual live broadcast to announce winners for the first time in the organization’s history.

Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Receives Department of Defense Award for Development of COVID-19 Vaccine

August 20, 2020 11:09 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus […]

APT Receives DoD Award for Development of COVID-19 Vaccine

August 19, 2020

News

Comments Off on APT Receives DoD Award for Development of COVID-19 Vaccine

GAITHERSBURG, Md., August 19, 2020 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the global rise of bacterial and viral infectious diseases, today announced the Department of Defense (DoD) awarded APT $9.8 million for research development of multiple high-priority, bacteriophage-based display vaccine candidates against the novel coronavirus (SARS-CoV-2). The effort will advance and evaluate […]

Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

News

Comments Off on Mayo Clinic as Lead Investor in Convertible Note Financing

Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed $1.75M as a lead investor in a $7 million convertible note financing round.

Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

August 5, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces Mayo Clinic as Lead Investor in Convertible Note Financing

— Proceeds to fund clinical trial for PhageBank treatment in periprosthetic joint infections — August 05, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced Mayo Clinic has committed […]

APT featured in Netflix Series

August 2, 2020

News

Comments Off on APT featured in Netflix Series

APT is featured in episode 2 of the Netflix series Connected. Science journalist Latif Nasser investigates the surprising and intricate ways in which we are connected to each other, the world and the universe.

APT and John Haverty featured in the Boston Globe

July 10, 2020

News

Comments Off on APT and John Haverty featured in the Boston Globe

For scientists, clinical trials like these are a first try. For participants, they are often a last hope. At the brink of giving up, John Haverty turned to internet research. He was aware of phage treatment [the therapeutic use of bacteriophages to treat bacterial infections like Haverty’s], and he happened across Maryland-based Adaptive Phage Therapeutics.

Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

June 9, 2020

Press Releases

Comments Off on Adaptive Phage Therapeutics Enters Agreement with Mayo Clinic to Commercialize a Phage Susceptibility Test

— Assay to rapidly match therapeutic phage to antibiotic-resistant infections — June 09, 2020 09:00 AM Eastern Daylight Time GAITHERSBURG, Md.–(BUSINESS WIRE)–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a […]

Collaboration with Mayo Clinic

June 9, 2020

News

Comments Off on Collaboration with Mayo Clinic

GAITHERSBURG, Md.–Mayo Clinic and Adaptive Phage Therapeutics (APT) today announced a collaboration to advance and commercialize a phage susceptibility test (PST) linked exclusively to APT’s PhageBank™ investigational therapy. At launch, the PST will be offered as a laboratory developed test for worldwide commercial availability by Mayo Clinic Laboratories (MCL). The PST will enable rapid identification […]